Sensei Biotherapeutics, Inc. (SNSE)
| Market Cap | 40.38M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -31.92M |
| Shares Out | 25.08M |
| EPS (ttm) | -1.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 303,773 |
| Open | 1.460 |
| Previous Close | 1.485 |
| Day's Range | 1.460 - 1.670 |
| 52-Week Range | 0.510 - 1.940 |
| Beta | 0.14 |
| Analysts | Strong Buy |
| Price Target | 4.50 (+183.02%) |
| Earnings Date | May 9, 2024 |
About SNSE
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pip... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for SNSE stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 183.02% from the latest price.
News
EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member
PARIS--(BUSINESS WIRE)--EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immuni...
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation s...
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutic...
Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference
BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer ...
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment
BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutic...
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutic...
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutic...
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade -
Sensei Biotherapeutics to Present at Upcoming Conferences
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics...
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
- Completed SNS-101 monotherapy dose escalation through 15 mg/kg with no dose limiting toxicities - - Expands patient cohort in specific tumor types - - Multiple clinical milestones expected in 2024 -...
Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- SNS-101 initial Phase 1 clinical data presented at SITC demonstrate potential best-in-class safety and pharmacokinetic profile, with no cytokine release syndrome or dose-limiting toxicities reported...
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
- Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encouraging cytokine release profile across multiple dose co...
Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics...
Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics...
Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023
BOSTON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics...
Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®
- Eleven patients enrolled overall in trial to date, with enrollment progressing faster than anticipated - - Monotherapy arm has advanced to a fourth cohort, with initial monotherapy PK and safety dat...
Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
- New data from multi-dose GLP toxicology study of SNS-101 in cynomolgus monkeys further support exceptional PK and safety profile -
Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
BOSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutic...
Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics...
Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Phase 1/2 clinical trial enrolling for lead investigational candidate SNS-101, a conditionally active VISTA-blocking antibody for the treatment of advanced solid tumors
Sensei Biotherapeutics to Participate in Canaccord Genuity's 43rd Annual Growth Conference
BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics...
Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors”
- Featuring Dr. James Gulley, Co-Director of the Center for Immuno-Oncology at the National Cancer Institute (NCI) and internationally recognized expert on cancer immunotherapy -
Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors
- Topline Phase 1 monotherapy and initial combination data expected in 2024 - BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage immuno-oncology co...
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics ...
Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
- Investigational New Drug (IND) application for SNS-101 cleared by U.S. Food and Drug Administration (FDA) with first patient dose in Phase 1/2 trial expected in mid-2023 -